Expert Insights on Key Updates From the 2022 ESMO Congress on PARP Inhibitors in Ovarian Cancer
In this podcast episode, listen to Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, discuss key updates for PARP inhibitor trials in ovarian cancer presented at the 2022 ESMO Congress, including the 7-year update from SOLO-1, final OS analyses for PAOLA-1, disease risk subgroup analysis from ATHENA-MONO, and OS results from ARIEL4.